The Musculoskeletal System in Systemic Lupus Erythematosus
- 1 January 2016
- book chapter
- Published by Elsevier
- p. 325-332
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Mediation of nonerosive arthritis in a mouse model of lupus by interferon‐α–stimulated monocyte differentiation that is nonpermissive of osteoclastogenesisArthritis & Rheumatism, 2010
- Osteonecrosis and Antiphospholipid SyndromeJCR: Journal of Clinical Rheumatology, 2009
- Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisArthritis & Rheumatism, 2007
- Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosusNature Clinical Practice Rheumatology, 2006
- Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control studyAnnals of the Rheumatic Diseases, 2006
- An Electron Microscopic Study of Muscle Capillary Wall Thickening in Systemic Lupus ErythematosusLupus, 1994
- Lupus myositisMuscle & Nerve, 1982